Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, et al. Major increase in human mpox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2010 [cited 2022 Aug 21];107:16262–7. Available from: /pmc/articles/PMC2941342/

Chen N, Li G, Liszewski MK, Atkinson JP, Jahrling PB, Feng Z, et al. Virulence differences between mpox virus isolates from West Africa and the Congo basin. Virology Academic Press. 2005;340:46–63.

CAS  Google Scholar 

Update: Multistate Outbreak of Mpox --- Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003 [Internet]. MMWR weekly. 2003 [cited 2022 Aug 21]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a5.htm

Mpox - United Kingdom of Great Britain and Northern Ireland [Internet]. [cited 2022 Oct 15]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON383

Mpox outbreak 2022 - Global [Internet]. [cited 2022 Aug 21]. Available from: https://www.who.int/emergencies/situations/mpox-oubreak-2022

Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Mpox virus infection in humans across 16 countries — April–June 2022. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2022 [cited 2022 Oct 8];387:679–91. Available from: https://doi.org/10.1056/NEJMoa2207323

Mpox: experts give virus variants new names [Internet]. [cited 2022 Oct 15]. Available from: https://www.who.int/news/item/12-08-2022-mpox--experts-give-virus-variants-new-names

Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of mpox virus. Nature Medicine 2022 28:8 [Internet]. Nature Publishing Group; 2022 [cited 2022 Oct 15];28:1569–72. Available from: https://www.nature.com/articles/s41591-022-01907-y

Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A tale of two clades: Mpox viruses. Journal of General Virology [Internet]. Microbiology Society; 2005 [cited 2022 Oct 15];86:2661–72. Available from: https://doi.org/10.1099/vir.0.81215-0

Bunge Id EM, Hoet Id B, Chen L, Lienert Id F, Weidenthalerid H, Baer LR, et al. The changing epidemiology of human mpox-A potential threat? A systematic review. 2022; Available from: https://doi.org/10.1371/journal.pntd.0010141

Harvala H, Simmonds P. Evaluating the risk of transfusion and transplant-transmitted mpox infections. Transfusion Medicine [Internet]. John Wiley & Sons, Ltd; 2022 [cited 2022 Oct 29]; Available from:https://doi.org/10.1111/tme.12918

• Yinka-Ogunleye A, Aruna O, Dalhat M, Ogoina D, McCollum A, Disu Y, et al. Outbreak of human mpox in Nigeria in 2017–18: a clinical and epidemiological report. Lancet Infect Dis [Internet]. Lancet Publishing Group; 2019 [cited 2022 Aug 21];19:872–9. Available from: http://www.thelancet.com/article/S1473309919302944/fulltext. This was a review of cases from the outbreak of mpox in Nigeria from 2017–2018 that suggested more severe outcomes from mpox in patients with HIV complicated by AIDS.

Ogoina D, Iroezindu M, James HI, Oladokun R, Yinka-Ogunleye A, Wakama P, et al. Clinical Course and Outcome of Human Mpox in Nigeria. Clinical Infectious Diseases [Internet]. Oxford Academic; 2020 [cited 2022 Aug 21];71:e210–4. Available from: https://academic.oup.com/cid/article/71/8/e210/5734993

•• Miller MJ, Cash-Goldwasser S, Marx GE, Schrodt CA, Kimball A, Padgett K, et al. severe mpox in hospitalized patients — United States, August 10–October 10, 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2022 Oct 25];71. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7144e1.htm. Described disease manifestations and outcomes for 57 cases of severe mpox the CDC was consulted on. Most patients the CDC was consulted on with severe disease were known to be immunocompromised.

HAN Archive - 00481 | Health Alert Network (HAN). https://emergency.cdc.gov/han/2022/han00481.asp. Accessed 28 Dec 2022

Menezes YR, Miranda AB de. Severe disseminated clinical presentation of mpox virus infection in an immunosuppressed patient: first death report in Brazil. Rev Soc Bras Med Trop [Internet]. Sociedade Brasileira de Medicina Tropical - SBMT; 2022 [cited 2022 Oct 8];55:2022. Available from: http://www.scielo.br/j/rsbmt/a/3nbnPmWjmgrwbLFWzX4tcGt/?lang=en

Texas reports death tied to mpox, a first in the U.S. - STAT [Internet]. [cited 2022 Oct 8]. Available from: https://www.statnews.com/2022/08/30/texas-reports-death-tied-to-mpox-a-first-in-the-u-s/

Mpox Death Confirmed by LA County Health Officials [Internet]. [cited 2022 Oct 10]. Available from: https://www.usnews.com/news/health-news/articles/2022-09-12/mpox-death-confirmed-by-la-county-health-officials

Pages - Maryland Department of Health announces human mpox-related death [Internet]. [cited 2022 Oct 29]. Available from: https://health.maryland.gov/newsroom/Pages/Maryland-Department-of-Health-announces-human-mpox-related-death.aspx

Menéndez García N, Mazón Ruiz J, de la Fuente Villaverde I, Bravo González-Blas L. Infección grave por viruela del mono en paciente trasplantado renal. Nefrología [Internet]. Elsevier; 2022 [cited 2022 Oct 1]; Available from: https://www.revistanefrologia.com/es-infeccion-grave-por-viruela-del-avance-S0211699522001473

Jang W, Kandimalla Gandhi Medical College Sivagami Rajan L, Abreu Hialeah Hospital Jamie Enrique Campos Hialeah Hospital Case Report R. Mpox in an immunocompromised patient with underlying human immunodeciency virus and syphilis infections in Southern Florida of the United States: A Case Report. 2022 [cited 2022 Oct 9]; Available from: https://doi.org/10.21203/rs.3.rs-2046790/v1

Boesecke C, Monin MB, van Bremen K, Schlabe S, Hoffmann C, Boesecke christophboesecke C. Severe mpox-virus infection in undiagnosed advanced HIV infection Keywords HIV · Mpox · MPX · Immunodeficiency · AIDS. 1901;1:3. Available from: https://doi.org/10.1007/s15010-022-01901-z

de Sousa D, Patrocínio J, Frade J, Correia C, Borges-Costa J, Filipe P. Human mpox coinfection with acute HIV: an exuberant presentation. Int J STD AIDS [Internet]. SAGE Publications Ltd; 2022 [cited 2022 Oct 15];33:936–8. Available from: https://journals.sagepub.com/doi/https://doi.org/10.1177/09564624221114998?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed

Lindholm DA, Fisher RD, Montgomery JR, Davidson W, Yu PA, Yu YC, et al. Preemptive tecovirimat use in an active duty service member who presented with acute myeloid leukemia after smallpox vaccination. Clinical Infectious Diseases [Internet]. Oxford Academic; 2019 [cited 2022 Oct 10];69:2205–7. Available from: https://academic.oup.com/cid/article/69/12/2205/5432316

Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis [Internet]. Oxford University Press; 2012 [cited 2022 Oct 2];206:1372. Available from: /pmc/articles/PMC3529603/

Dato V, Moose C, Rea N, Fraser G, Seider J, Rittle C, et al. Human vaccinia infection after contact with a raccoon rabies vaccine bait --- Pennsylvania, 2009 [Internet]. 2009 Nov. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5843a2.htm

Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. http://dx.doi.org/101056/NEJM198703123161106 [Internet]. Massachusetts Medical Society ; 2010 [cited 2022 Oct 10];316:673–6. Available from: https://doi.org/10.1056/NEJM198703123161106

Wendt R, Tittelbach J, Schrick L, Kellner N, Kalbitz S, Ruehe B, et al. Generalized cowpox virus infection in an immunosuppressed patient. International Journal of Infectious Diseases [Internet]. Elsevier B.V.; 2021 [cited 2022 Aug 21];106:276–8. Available from: http://www.ijidonline.com/article/S1201971221002940/fulltext

Gazzani P, Gach JE, Colmenero I, Martin J, Morton H, Brown K, et al. Fatal disseminated cowpox virus infection in an adolescent renal transplant recipient. Pediatr Nephrol. 2017;32(3):533–6. https://doi.org/10.1007/s00467-016-3534-y.

Article  Google Scholar 

Geerinck K, Lukito G, Snoeck R, de Vos R, de Clercq E, Vanrenterghem Y, et al. A case of human Orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol [Internet]. John Wiley & Sons, Ltd; 2001 [cited 2022 Oct 9];64:543–9. Available from:https://doi.org/10.1002/jmv.1084

Tan ST, Blake GB, Chambers S. Recurrent orf in an immunocompromised host. Br J Plast Surg Churchill Livingstone. 1991;44:465–7.

Article  CAS  Google Scholar 

Siddiqui N, Mansfield BS, Olmesdahl N-P, Swart P, Nel J. A severe case of molluscum contagiosum immune reconstitution inflammatory syndrome in a patient with human immunodeficiency virus. Eur J Case Rep Intern Med [Internet]. European Federation of Internal Medicine; 2022 [cited 2022 Aug 21];9. Available from: /pmc/articles/PMC8833301/

Kaufman W, Ahn C, Huang W. Molluscum contagiosum in immunocompromised patients: AIDS presenting as molluscum contagiosum in a patient with psoriasis on biologic therapy | MDedge Dermatology. Cutis [Internet]. 2018 [cited 2022 Oct 11];101:136–40. Available from: https://www.mdedge.com/dermatology/article/158024/psoriasis/molluscum-contagiosum-immunocompromised-patients-aids

Mansur AT, Göktay F, Gündüz S, Serdar ZA. Multiple giant molluscum contagiosum in a renal transplant recipient. Transplant Infectious Disease [Internet]. John Wiley & Sons, Ltd; 2004 [cited 2022 Oct 9];6:120–3. Available from: https://onlinelibrary.wiley.com/doi/full/https://doi.org/10.1111/j.1399-3062.2004.00060.x

Ibarra V, Blanco J, Oteo J, Rosel L. Ef®cacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm Venereol. 2000;80:315.

Article  CAS  Google Scholar 

Clinical Considerations for Pain Management of Mpox | Mpox | Poxvirus | CDC [Internet]. [cited 2022 Oct 15]. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/pain-management.html

Interim Clinical Considerations for Management of Ocular Mpox Virus Infection | Mpox | Poxvirus | CDC [Internet]. [cited 2022 Oct 15]. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/ocular-infection.html

Jay Montgomery CR. Ocular vaccinia: a consequence of unrecognized contact transmission. Mil Med [Internet]. 2011 [cited 2022 Oct 15];176:699. Available from: https://academic.oup.com/milmed/article/176/6/699/4345460

Mpox | NIH [Internet]. [cited 2022 Oct 15]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/mpox?view=full

Mpox in the U.S.: Resources for HIV Clinicians [Internet]. [cited 2022 Oct 15]. Available from: https://www.hivma.org/globalassets/idsa/public-health/mpox/mpv-hiv-clinician-resource-brief.pdf

Clinical considerations for treatment and prophylaxis of mpox virus infection in people with HIV | Mpox | Poxvirus | CDC [Internet]. [cited 2022 Oct 15]. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/people-with-HIV.html

CDC. Expanded access IND protocol: use of tecovirimat (TPOXX ® ) for treatment of human non-variola orthopoxvirus infections in adults and children. 2022 [cited 2022 Oct 2]; Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/obtaining-tecovirimat.html

O’Shea J, Filardo TD, Morris SB, Weiser J, Petersen B, Brooks JT. Interim Guidance for Prevention and Treatment of Mpox in Persons with HIV Infection — United States, August 2022. MMWR Morb Mortal Wkly Rep [Internet]. 2022 [cited 2022 Aug 21];71:1023–8. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7132e4.htm

Access Data FDA. Vistide (Cidofovir injection) [Internet]. [cited 2022 Oct 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/020638s003lbl.pdf

HIGHLIGHTS OF PRESCRIBING INFORMATION. TEMBEXA (brincidofovir) [Internet]. [cited 2022 Oct 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214460s000,214461s000lbl.pdf

HIGHLIGHTS OF PRESCRIBING INFORMATION. CNJ-016, Vaccinia immune globulin intravenous (human), sterile solution. [cited 2022 Oct 5]; Available from: https://www.fda.gov/medwatch.

• Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral tecovirimat for the treatment of smallpox. New England Journal of Medicine [Internet]. Massachusetts Medical Society; 2018 [cited 2022 Aug 21];379:44–53. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1705688. This was the tecovirimat trial that led to FDA approval for smallpox under the animal efficacy rule. It showed it was efficacious in two animal models and safe in an expanded human safety trial.

Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol [Internet]. American Society for Microbiology; 2005 [cited 2022 Oct 1];79:13139–49. Available from: https://doi.org/10.1128/JVI.79.20.13139-13149.2005

Berhanu A, Prigge JT, Silvera PM, Honeychurch KM, Hruby DE, Grosenbach DW. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for mpox virus infection. Antimicrob Agents Chemother [Internet]. American Society for Microbiology; [cited 2022 Oct 1];59:4296–300. Available from. 2015. https://doi.org/10.1128/AAC.00208-15.

Article  Google Scholar 

HIGHLIGHTS OF PRESCRIBING INFORMATION. TPOXX [Internet]. [cited 2022 Oct 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214518s000lbl.pdf

Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, et al. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2010 [cited 2022 Oct 1];107:838. Available from: /pmc/articles/PMC2818887/

FDA Mpox Response | FDA [Internet]. [cited 2022 Oct 2]. Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/fda-mpox-response

Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, mpox and other orthopoxvirus infections. Antiviral Res Elsevier. 2003;57:13–23.

Article  CAS  Google Scholar 

Quenelle DC, Collins DJ, Kern ER. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother [Internet]. American Society for Microbiology (ASM); 2003 [cited 2022 Oct 3];47:3275. Available from: /pmc/articles/PMC201130/

Stittelaar KJ, Neyts J, Naesens L, van Amerongen G, van Lavieren RF, Holy´6 A, et al. Antiviral treatment is more effective than smallpox vaccination upon lethal mpox virus infection. Nature. 2006;439(7077):745–748. https://doi.org/10.1038/nature04295

Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. The Journal of Infectious Diseases [Internet]. 2000;181:10–9. Available from: https://academic.oup.com/jid/article/181/1/10/890814

Andrei G, Gammon DB, Fiten P, de Clercq E, Opdenakker G, Snoeck R, et al. cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol [Internet]. American Society for Microbiology; 2006 [cited 2022 Oct 3];80:9391–401. Available from: https://journals.asm.org/journal/jvi

FDA approves drug to treat smallpox | FDA [Internet]. [cited 2022 Oct 15]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox

Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC [Internet]. [cited 2022 Oct 15]. Available from: https://www.cdc.gov/poxvirus/mpox/clinicians/treatment.html

Grossi IM, Foster SA, Gainey MR, Krile RT, Dunn JA, Brundage T, et al. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits. Antiviral Res Elsevier. 2017;143:278–86.

Article  CAS  Google Scholar 

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, et al. Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res Elsevier. 2008;77:39–49.

Article  CAS  Google Scholar 

Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human mpox: a retrospective observational study in the UK. Lancet Infect Dis. Elsevier BV; 2022;

Cono J, Casey C, Bell D. MMWR. Smallpox vaccination and adverse reactions: guidance for clinicians [Internet]. [cited 2022 Oct 5]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5204a1.htm

US FDA. Package insert - JYNNEOS [Internet]. 2019 [cited 2022 Oct 10]. Available from: https://www.fda.gov/media/131078/download

US FDA. ACAM2000 Product Insert [Internet]. 2007 [cited 2022 Oct 10]. Available from: https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert---ACAM2000.pdf

Rafii-El-Idrissi Benhnia M, McCausland MM, Su H-P, Singh K, Hoffmann J, Huw Davies D, et al. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol. 2008;82:3751–68.

Article  Google Scholar 

Nguyen PY, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR. Reemergence of human mpox and declining population immunity in the context of urbanization, Nigeria, 2017–2020. Emerg Infect Dis. Centers for Disease Control and Prevention (CDC); 2021;27:1007–14.

Hatch GJ, Graham VA, Bewley KR, Tree JA, Dennis M, Taylor I, et al. Assessment of the protective effect of Imvamune and Acam 2000 vaccines against aerosolized mpox virus in Cynomolgus macaques. J Virol. 2013;87(14):7805–15. https://doi.org/10.1128/JVI.03481-12.

Article  CAS  Google Scholar 

Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against mpox [Internet]. Nature. 2004;428(6979):182–5. https://doi.org/10.1038/nature02331.Availablefrom:www.nature.com/nature.

Article  CAS  Google Scholar 

Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FHM, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with mpox virus. J Virol. 2005;79:7845–51.

Article  CAS  Google Scholar 

Smith YE-, Venzon D, Karpova T, Mcnally J, Nacsa J, Tsai W-P, et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. Smallpox Vaccination AIDS Model. JID. 2003;1181.

Edghill-Smitli Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, et al. Smallpox vaccine does not protect macaques with AIDS from a lethal mpox virus challenge. Journal of Infectious Diseases [Internet]. Oxford Academic; 2005 [cited 2022 Aug 21];191:372–81. Available from: https://academic.oup.com/jid/article/191/3/372/794854

Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against mpox virus. Nat Med. 2005;11(7):740–747. doi:https://doi.org/10.1038/nm1261 [cited 2022 Aug 22]; Available from: http://www.nature.com/naturemedicine

• Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015;2(2):ofv040. Published 2015 May 5. doi:https://doi.org/10.1093/ofid/ofv040 [cited 2022 Oct 10]; Available from: https://academic.oup.com/ofid/article-abstract/2/2/ofv040/1411319. This was a clinical phase 2 trial that showed comparable safety and immunogenicity profile of the 2-dose Modified Vaccinia Ankara-Bavarian Nordic Smallpox vaccine series in people living with HIV versus HIV uninfected comparators. Notably, this trial excluded any people living with HIV with a CD4 cell count <200 cells/mm3, and the vast majority of trial participants were virally suppressed on antiretroviral therapy.

Greenberg RN, Turner Overton E, Haas DW, Frank I, Goldman M, von Krempelhuber A, et al. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects. J Infect Dis; Mar 1 2013.

Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, et al. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013;207(12):1888–1897. https://doi.org/10.1093/infdis/jit105 [cited 2022 Oct 10]; Available from: http://www.niaid.nih.gov/

Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. New England Journal of Medicine. Massachusetts Medical Society; 2019;381:1897–908.

• Payne AB, Ray LC, Kugeler KJ, Fothergill A, White EB, Canning M, et al. Incidence of mpox among unvaccinated persons compared with persons receiving ≥1 JYNNEOS vaccine dose — 32 U.S. Jurisdictions, July 31–September 3, 2022. MMWR. [cited 2022 Oct 10]; Available from: https://www.cdc.gov/poxvirus/mpox/response/2022/vaccines_data.html. This was a MMWR report on JYNNEOS vaccine efficacy that showed decreased mpox incidence among vaccinated individuals. No sub-analysis data are currently available to evaluate effect of underlying immune-compromising condition on disease incidence among those vaccinated.

Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, el Sahly H, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine Elsevier Ltd. 2015;33:5225–34.

CAS  Google Scholar 

Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak | Mpox | Poxvirus | CDC [Internet]. [cited 2022 Oct 31]. Available from: https://www.cdc.gov/poxvirus/mpox/health-departments/vaccine-considerations.html

Mpox FAQs for Transplant Community | American Society of Transplantation [Internet]. [cited 2022 Oct 31]. Available from: https://www.myast.org/mpox-faqs-transplant-community

Technical Report 4: Multi-National Mpox Outbreak, United States, 2022 | Mpox | Poxvirus | CDC [Internet]. [cited 2022 Oct 31]. Available from: https://www.cdc.gov/poxvirus/mpox/cases-data/technical-report/report-4.html

Study of Tecovirimat for Human Mpox Virus - Full Text View - ClinicalTrials.gov [Internet]. [cited 2022 Oct 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT05534984

Tecovirimat for Treatment of Mpox Virus - Full Text View - ClinicalTrials.gov [Internet]. [cited 2022 Oct 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT05559099

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Mpox | SIGA [Internet]. [cited 2022 Oct 31]. Available from: https://investor.siga.com/news-releases/news-release-details/siga-provides-update-progress-clinical-trials-assess-use-tpoxx-r